Kamada Ltd logo


Kamada Ltd


Earnings Summary

Net Profits
Net Profit Margins



Kamada Ltd’s revenue jumped 12.82% since last year same period to $28.09Mn in the Q1 2022. On a quarterly growth basis, Kamada Ltd has generated -10.73% fall in its revenue since last 3-months.

Net Profits:

Kamada Ltd’s net profit fell -168.03% since last year same period to $-1.83Mn in the Q1 2022. On a quarterly growth basis, Kamada Ltd has generated 63.51% jump in its net profits since last 3-months.

Net Profit Margins:

Kamada Ltd’s net profit margin fell -160.3% since last year same period to -6.51% in the Q1 2022. On a quarterly growth basis, Kamada Ltd has generated 59.12% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Kamada Ltd post its latest quarter earnings

EPS Estimate Current Quarter
EPS Estimate Current Year


EPS Estimate Current Quarter:

Kamada Ltd’s earning per share (EPS) estimates for the current quarter stand at 0.03 - a 400% jump from last quarter’s estimates.

EPS Estimate Current Year:

Kamada Ltd’s earning per share (EPS) estimates for the current year stand at 0.03.

Key Ratios

Key ratios of the Kamada Ltd post its Q1 2022 earnings

Earning Per Share (EPS)
Return on Assets (ROA)
Return on Equity (ROE)
Dividend Per Share (DPS)


Earning Per Share (EPS):

Kamada Ltd’s earning per share (EPS) fell -166.67% since last year same period to -0.04 in the Q1 2022. This indicates that the Kamada Ltd has generated -166.67% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kamada Ltd’s return on assets (ROA) stands at -0.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kamada Ltd’s return on equity (ROE) stands at -0.04.

Dividend Per Share (DPS):

Kamada Ltd declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %

Company Information

Kamada Ltd. (the 'Company') is a global specialty plasma-derived biopharmaceutical company with a diverse portfolio of marketed products, a robust development pipeline and industry-leading manufacturing capabilities. The Company's strategy is focused on driving profitable growth from its current commercial products, its plasma-derived development pipeline and its manufacturing expertise, while evolving into a vertically integrated plasma-derived company. The Company's two leading commercial products are GLASSIA® and KEDRRAB®. GLASSIA was the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the FDA. The Company markets GLASSIA in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited ('Takeda') and in other countries through local distributors. Pursuant to an agreement with Takeda, the Company will continue to produce GLASSIA for Takeda through 2021 and Takeda will initiate its own production of GLASSIA for the U.S. market in 2021, at which point Takeda will commence payment of royalties to the Company until 2040. KEDRAB is an FDA approved anti-rabies immune globulin (Human) for post-exposure prophylaxis treatment. KEDRAB is being marketed in the U.S. through a strategic partnership with Kedrion S.p.A. The Company has additional four plasma-derived products administered by injection or infusion, that are marketed through distributors in more than 15 countries, including Israel, Russia, Brazil, Argentina, India and other countries in Latin America and Asia. The Company has two leading development programs; a plasma-derived hyperimmune immunoglobulin (IgG) product as a potential treatment for coronavirus disease (COVID-19) and an inhaled AAT for the treatment of AAT deficiency for which the Company is currently conducting the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. The Company leverages its expertise and presence in the Israeli pharmaceutical market to distribute in Israel more than 20 products that are manufactured by third parties and have recently added nine biosimilar products to its Israeli distribution portfolio, which, subject to EMA and the Israeli MOH approvals, are expected to be launched in Israel between the years 2022 and 2025. FIMI Opportunity Fund, the leading private equity investor in Israel, is the Company's lead shareholder, beneficially owning approximately 21% of the outstanding ordinary shares.

Kamada Ltd
Health Technology